Results 241 to 250 of about 45,189 (317)

Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk.

JAMA Netw Open
Sendaydiego X, Gold LS, Dubreuil M, Andrews JS, Reid P, Liew DFL, Goulabchand R, Singh AG, Hughes GC, Pioro M, Sparks JA, Jarvik JG, Singh S, Liew JW, Singh N.   +14 more
europepmc   +1 more source

Trends in the use of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and recently diagnosed colorectal, lung, or prostate cancer. [PDF]

Clin Rheumatol
Suarez-Almazor ME, Ruiz JI, Lei X, Wu CF, Zhao H, Rajan SS, Giordano SH.   +6 more
europepmc   +1 more source

OP0090 Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis

André Lucas Ribeiro, V. Carrizo Abarza, Jensen Yeung, Khalad Maliyar, Sanjeev Sood, Ahmed Bagit, Muskaan Sachdeva, Sahil Koppikar, Dafna D. Gladman, V. Chandran, L. Eder   +10 more
openalex   +1 more source

Factors predicting treatment response to biological and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review and meta-analysis. [PDF]

Clin Rheumatol
Künzler T, Bamert M, Sprott H.
europepmc   +1 more source

Influencers of Achievement of Remission and Low Disease Activity in Response to Disease-Modifying Antirheumatic Drugs (DMARDs) in Patients With Rheumatoid Arthritis. [PDF]

Cureus
Oyoo GO, Guantai A, Moots RJ, Okalebo F, Osanjo GO.   +4 more
europepmc   +1 more source

Letter to the Editor Regarding: "Incidence of Malignancies and the Association with Biological Disease-Modifying Antirheumatic Drugs in Japanese Patients with Rheumatoid Arthritis: A Time-Dependent Analysis from the IORRA Patient Registry". [PDF]

Rheumatol Ther
Liu Z, Tian M, Duan L.
europepmc   +1 more source

Toxicities Associated with Continuing Disease-Modifying Antirheumatic Drugs for Collagen Vascular Diseases During Head and Neck Intensity-Modulated Radiotherapy: A Single-Institution Experience. [PDF]

J Otolaryngol Head Neck Surg
Ni L, Phuong C, Yom SS, Chan JW.
europepmc   +1 more source

Major adverse cardiovascular events or venous thromboembolism in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a nationwide, population-based cohort study. [PDF]

Ther Adv Musculoskelet Dis
Kao CM, Chen YJ, Chen YM, Chen DY, Chen HH.   +4 more
europepmc   +1 more source